key: cord-0874299-tkaci72t authors: Naghavi, Saba; Kavosh, Aryan; Adib, Iman; Shaygannejad, Vahid; Arabi, Sina; Rahimi, Maryam; Mazaheri, Shahbanoo; Ashtari, Fereshteh title: COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: what we know by May 2021 date: 2021-10-16 journal: Mult Scler Relat Disord DOI: 10.1016/j.msard.2021.103335 sha: 0dbfc06475c74842b79528a9316da67a76a68940 doc_id: 874299 cord_uid: tkaci72t BACKGROUND: : Despite investigations on the effect of disease modifying therapies (DMTs) used in multiple sclerosis (MS) on coronavirus disease 2019 (COVID-19); there are still controversies. OBJECTIVE: : We designed this study to evaluate the epidemiological features of covid-19 in a large sample of people with MS (pwMS) in Isfahan, Iran, as well as the association between DMTs, risk of COVID-19 infection and hospitalization. METHODS: : In an observational pwMS, we interviewed subjects on their MS and COVID-19 history. RESULTS: : 3050 subjects were included (74% female) with a mean age of 41.36. 423 (13.8%) had confirmed COVID-19 which shows that pwMS are at a higher risk of infection compared to the general population, No significant relationship was observed in COVID-19 infection when individual drugs. Dimethyl fumarate and rituximab had the lowest and the highest relative risks for hospitalization rate compared to other drugs, respectively. CONCLUSION: : We found no evidence supporting a higher prevalence of COVID-19 in pwMS compared to the general population. However, our results show pwMS to be more prone to hospitalization compared to the general population, Therefore, it is advised to use safer treatment if possible until complete vaccination, and to postpone the use of rituximab. Objective: We designed this study to evaluate the epidemiological features of covid-19 in a large sample of people with MS (pwMS) in Isfahan, Iran, as well as the association between DMTs, risk of COVID-19 infection and hospitalization. Methods: In an observational pwMS, we interviewed subjects on their MS and COVID-19 history. Results: 3050 subjects were included (74% female) with a mean age of 41.36. 423 (13.8%) had confirmed which shows that pwMS are at a higher risk of infection compared to the general population. Acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in January 2020 due to its causative role in coronavirus disease 2019 (COVID- 19) 4 . The disease, first reported in Wuhan in Hubei province of China alarmingly spread throughout the world, which led to the declaration of COVID-19 as a pandemic by the World health organization (WHO) on 11 March 2020. 5 As of June 9 2021 more than 186 million cases and 4 million deaths have been reported 6 . Immunocompromised patients seem to be at a higher risk of COVID-19 infection and also in danger of more severe forms of the disease. This was also suspected to be the case with people living with MS (pwMS) also, who have weaker immune systems due to the nature of the disease and the therapeutic strategies currently used: both disease modifying therapies (DMT) which are used to decrease the number of relapses and corticosteroids which are mainstays of treatment in acute attacks make patients immunocompromised and increases their infection risk 7 8 . The results of various studies trying to address the issue of MS and the treatment implications for COVID-19, indicating a high risk for SARS-CoV-2 infection 9 as well as more severe infection 10 in pwMS. Recent reviews however, have attributed such observations to older age and other comorbidities and do not consider MS or DMTs (with the exception of anti-CD20 therapies) as risk factors for severe COVID-19 11 . Despite the accumulated evidence on the subject, most investigations have reported being limited by small sample sizes and were conducted early in the pandemic when there was much less knowledge on COVID-19. We designed this study to evaluate the epidemiological features of covid-19 in a large sample of pwMS in Isfahan, Iran, as well as the association between DMT, disease course, and disability in this population with risk of COVID-19 infection and rate of hospitalization. Study design: This was a cross-sectional observational study conducted on pwMS in Isfahan (an Iranian province with high MS prevalence 12 ). Study protocol was approved by the ethics committee of Isfahan University of medical sciences. Participants: All pwMS 18 and older with definite MS according to McDonald's criteria 13 , who were registered at Kashani Comprehensive MS center (the main registered database in Isfahan) and were invited to receive the first dose of COVID-19 vaccine were included. Data collection: pwMS were explained the process and aims of the study and nearly all of them agreed to be included. Those who chose to participate underwent a semi-structured medical interview before receiving the first dose of vaccine. The interview session consisted of medical history taking focused on demographic and disease characteristics (presenting symptoms, disease course Annual relapse rate (ARR), phenotype, current disability status according to Mann-Whitney U test was used to compare differences between non-parametric variables when the dependent variable is either ordinal or continuous; for categorical variables Pearson's chi-square test was performed. In order to compare the risk of using DMTs and their effect on hospitalization risk, drugs were compared in pairs by Fisher's exact test and the relative risk (RR) was calculated with 95% confidence interval (CI). Population characteristics 3050 subjects were included in the study of which 2259 (74%) were female with a mean age of 41.36 ± 10.39 (SD). The average duration of MS was 10.54 ± 6.94 and the most prevalent phenotype was RRMS (56.7%) and 91.2% were on disease modifying therapies. 623 (20.4%) had a history of COVID-19 diagnosis of which 356 (57%) had been confirmed via a positive PCR, 67 (10.7%) via HRCT-scan findings (a total of 423 (13.8%) of the subjects having definite COVID-19 history) and the rest were diagnosed only by clinical judgment and contact tracing without further paraclinical evidence. There was no relation between ARR and risk of COVID-19 infection (P-value = 0.261). Further data on demographic characteristics, MS disease features and therapies and COVID-19 infection are presented in table 1. Comorbidity was present in 20.1% of women compared to 14.6% of men (P-value = 0.001). The most common comorbidities among women were hypothyroidism (6.3%) and hypertension (2.7%), and the one most commonly observed in men was diabetes (2.5%) as detailed in table 1. Women had lower EDSS scores than men (2.03 ± 2.90 vs 2.39 ± 2.45; P-value < 0.001) and received more DMTs (92.8% vs. 87.65%; P-value <0.001). Hospitalization rate due to COVID-19 infection was significantly lower in women compared to men (1.55% vs. 3.29%; P-value < 0.001) despite no significant difference in COVID-19 infection history (P-value = 0.089) Further differences between the sexes and are presented in table 1. Compared to pwMS on DMTs, those who did not take medication for MS were less likely develop COVID-19 infection (17.6% vs. 20.7%; P-value = 0.240), but had a significantly higher hospitalization rate (21.7% vs. 8.9%; P-value = 0.005). pwMS taking no drugs also had a significantly higher EDSS score (4.12 ± 5.37 vs. 1.94 ± 2.33; P-value <0.001). No significant association was observed between different classes of DMTs and risk of having definite (supported by PCR or HRCT) (P-value = 0.068) or suspected (P-value = 0.025) COVID-19 infection. In terms of hospitalization risks, dimethyl fumarate had lowest relative risks compared to other widely used drugs, reaching a statistically significant difference when compared to rituximab (P-value <0.001; RR=0.159; CI = [0.04-0.61]), followed by both low dose and high dose interferons which showed lower risk compared to most of the other drugs. On the other hand, rituximab was associated with highest odd ratios, having statistically significant higher risks in comparison with low dose interferons (P-value <0.001; RR=1.740; CI = [1.45-2.08]) and dimethyl fumarate, as mentioned before. Further data on hospitalization risk of different DMTs is presented in table 2. Out of 3050 pwMS, 20.4% had confirmed or suspected COVID-19 and a total of 356 (11.7%) had a positive PCR result. This is not very different than the general Iranian population which was reported to have a 14.2% prevalence of COVID-19 by Khalaghi et al. 14 Our results support the conclusion that pwMS are not in an increased risk of COVID-19 which has also been reached Fernandes et al. 15 , Kovvuru et al. 16 and Moreno-Torres et al. 17 In terms of hospitalization, we observed 9.7% rate among those who had a positive COVID-19 diagnosis. While still higher than the rate of 4% expected in the general population 21 , it is considerably lower than the 25% risk reported in the Iranian MS population reported by Sahraian et al 18 . The reduction could be attributed to the fact that more people in Iran have been cooperating with mask mandates and physical distancing measures as reported by government 22 , a practice which has been shown to decrease hospitalization rates by Joo et al 23 . It is also of note that in a report of Iranian pwMS, the subjects showed a relatively acceptable awareness on COVID-19 24 . While the decline could be seen optimistically as a sign of less severe COVID-19 in pwMS, hospitalization rate is still higher than the general population, an observation that has been reported in several studies 25 26 27 and necessitates further efforts for vaccination and management strategies. We also found that higher disability was associated with a higher likelihood of hospitalization, a finding which remains largely uncontroversial as the relationship between higher EDSS scores and severe COVID-19 has been observed by Louapre et al. and others 25 28, 29 . EDSS and hospitalization risk was also higher in those who were taking no medication for their disease (likely due to progressive course of the disease and lack of response to treatment). It could be argued that their disability leads to a lack of community attendance and more adherence to health protocols, resulting in fewer infections, but this disability results in a more severe illness and need for hospitalization. It is also of note that a significantly higher hospitalization risk seen in men, supporting the role of sex as a risk factor for severe COVID-19 which has been observed in numerous studies 30 31, 32 . The lower hospitalization rate in women was observed despite their higher prevalence of comorbidities compared to men, This could be explained by the fact that the most prevalent comorbidity in our population (observed significantly more in women) was hypothyroidism which does not seem to affect COVID-19 severity 33 34 . The comorbidities suggested to be risk factors for severe COVID-19 as such for hypertension and diabetes mellitus 31, 32 were not significantly different between the two sexes, despite being the second and third most prevalent comorbidities overall. In a study of COVID-19 in pwMS in the USA Reder et al. reported the most prevalent comorbidities to be hypertension and diabetes mellitus 20 and Sepúlveda et al. found the most prevalent comorbidity to be dyslipidemia, followed by hypertension and diabetes mellitus in a Spanish population 19 . This shows a generally similar comorbidity profile in pwMS studies across countries. There was no significant relationship between the risk of having COVID-19 and the type of DMTs used. A finding that has been reported multiple times in different investigations since early on in the pandemic in research by Somrani et al. 35 and others 36 9 25 28 . It should be born in mind however that there have been different results: there have been reports of anit-CD20 therapies increasing infection risk by Reder et al. 19 and Safavi et al. 37 It is of note that our data might be affected by a bias due to relying on people to recall their COVID-19 and MS history. It is of note however that nearly all of pwMS who met the inclusion criteria agreed to participate in the study. We found no evidence supporting a higher prevalence of COVID-19 in pwMS compared to the general population. However, our results show pwMS to be more prone to hospitalization compared to the general population. Although no relation was found between individual DMT drugs and risk of COVID-19 infection, rituximab had a significantly higher risk of hospitalization compared to other treatments and dimethyl fumarate had a lower risk. Therefore, it is advised to use safer treatment if possible until complete vaccination, and to postpone the use of immunosuppressive drugs such as rituximab. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS Multiple sclerosis The first 12 months of COVID-19: a timeline of immunological insights In MS: Immunosuppression is passé. Multiple sclerosis and related disorders 2020 Infection Risk and Safety of Corticosteroid Use. Rheumatic diseases clinics of Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy. Multiple sclerosis and related disorders 2020 Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies Review of the COVID-19 Risk in Multiple Sclerosis Multiple sclerosis in Isfahan Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases Impact of the first COVID-19 pandemic wave on the Scottish Multiple Sclerosis Register population Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic Risk and outcomes of COVID-19 in patients with multiple sclerosis Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Multiple sclerosis and related disorders 2020 COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies Incidence and Impact of COVID-19 in MS: A Survey From a Barcelona MS Unit Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study Decline in COVID-19 Hospitalization Growth Rates Associated with Statewide Mask Mandates -10 States Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran. Multiple sclerosis and related disorders 2020 Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Multiple sclerosis and related disorders 2021 Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis Outcomes of Patients With Hypothyroidism and COVID-19: A Retrospective Cohort Study Thyroid disease in the time of COVID-19 An Italian programme for COVID-19 infection in multiple sclerosis Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Multiple sclerosis and related disorders 2020 Disease-Modifying Therapies and Coronavirus Disease Safari A, Khodabandeh Z and Borhani-Haghighi A. Dimethyl Fumarate Can Enhance the Potential Therapeutic Effects of Epidermal Neural Crest Stem Cells in COVID-19 Patients Multiple sclerosis, rituximab, and COVID-19 Funding: this research was funded by Isfahan University of Medical Sciences.